The February 2019 digital edition includes MM&M’s second annual Data Issue, plus a look back at the JP Morgan Healthcare conference.
Belle Frank is chief strategy officer, global health practice at VMLY&R.
Marketers answer the question: How can AI, marketing tech, and sophisticated analytics be used to help find participants for clinical research?
For many people, disease awareness campaigns represent the first true beginning of hope — which is why these stories are so impactful and important to tell.
President Trump’s blueprint to lower drug prices hasn’t made it out of the brainstorm phase.
Tod Loofbourrow is CEO of ViralGains.
Texas Judge Reed O’Connor’s ruling on the ACA could affect both insurers and pharma.
Biopharma’s quest to harness tech should be accompanied by a healthy dose of skepticism.
The 2019 Data Issue includes features on data privacy, pharma’s data architects, and the use of data in marketing programs.
Three of the industry’s top data architects reflect on their careers, opine on pharma’s “data revolution,” muse on the future of AI in healthcare, and unravel the secrets of their universe.
Get to know each of these companies by learning about their culture, work/life balance, D&I initiatives and more.
OptimizeRx’s Chris DiCostanzo and Rebecca Love explain the value of reaching patients and HCPs when it matters most.
Talking Medicines’ Jo Halliday discussed how the pharmaceutical sector can better understand the voice of the patient.
Learn about Intouch Group’s journey to foster I+D so that its inclusive culture translates into inclusive healthcare marketing.
Any EHR provider delivering a quality solution should be able to answer these six questions.
Please login or register first to view this content.